InvestorsHub Logo
Followers 41
Posts 1956
Boards Moderated 0
Alias Born 03/24/2014

Re: Evaluate post# 14909

Sunday, 06/29/2014 11:15:39 AM

Sunday, June 29, 2014 11:15:39 AM

Post# of 699277
Evaluate, I for one find value in many of these videos/articles referring to Immuno Oncology even if the focus is not specifically on NWBO's product. It just further validates the science and technology and where treatment is heading. You couple this with how much work has been done by NWBO over the past 10+ yrs and the infrastructure they have already set up over in Germany and UK. We are the frontrunners (Other cancer vaccines are also forecast to hit the glioblastoma market by 2019, including Celldex Therapeutics' Rindopepimut and Peregrine Pharmaceuticals' targeted therapy Cotara) in the pack and that I why I think we (NWBO) is being attacked so viciously right now!Who else has what we have in Germany? We will begin to see $$$$$ coming in by Q3/Q4 which will take some pressure off our balance sheet. I truly hope we don't partner and go at this alone b/c the payoff will be that much better and I am certain that is the way LP sees it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News